parp15

PARP10-IN-2 is a potent inhibitor of PARP10, a mono-ADP-ribosyltransferase, with an IC50 value of 3.64 μM for human PARP10. It also inhibits PARP2 and PARP15, with IC50 values of 27 μM and 11 μM, respectively.

RBN-3143 is a potent inhibitor of NAD+-competitive catalytic PARP14 (IC50= 4 nM), which inhibits ADP-ribosylation mediated by PARP14 and stabilizes PARP14 in cell lines, demonstrating research potential for lung inflammation.

PARP10-IN-3 is a potent and selective mono-Adp-ribotransferase PARP10 inhibitor that inhibits human PARP10 (IC50:480 nM). PARP10-IN-3 also inhibited human PARP2 and human PARP15 with IC50 values of 1.7 μM.

OUL243 is a potent and selective inhibitor of mono-ADP-ribosyltransferase (ARTs), effectively suppressing PARP7, PARP10, PARP11, PARP12, PARP14, and PARP15.

PARP10 15-IN-3 (Compound 8a) is a potent dual inhibitor of PARP10 and PARP15 with IC50 values of 0.14 μM and 0.40 μM, respectively. It can enter cells and prevent apoptosis [1].

PARP10 15-IN-1 (compound 8l) is a dual inhibitor of PARP10 and PARP15, with IC50 values of 160 nM and 370 nM, respectively. It is applicable in cancer research[1].

YCH1899, an orally active PARP inhibitor, demonstrates potent inhibition of PARP1 2 with an IC50 of less than 0.001 nM. It shows marked antiproliferative efficacy against Olaparib-resistant (Capan-1 OP) and Talazoparib-resistant (Capan-1 TP) cells with IC50 values of 0.89 nM and 1.13 nM, respectively. Moreover, YCH1899 possesses favorable pharmacokinetic attributes in rats [1].

RBN012759 inhibits PARP14 protein with an IC50 value of 0.003 μM and is more than 300-fold selective over all PARP family members.[2]

OUL245, a 7-Hydroxy derivative, selectively inhibits PARP2 with an IC50 of 44 nM. Additionally, it exhibits inhibition against other PARP and TNKS enzymes, displaying IC50 values ranging from 2.9 to 8.8 μM.

ART-IN-1 (compound 7) is a selective inhibitor of PARP with IC50 values of 19 μM for PARP2, 22 μM for TNKS2, 2.4 μM for PARP10, >100 μM for PARP14, and 1.1 μM for PARP15 [1].

ARTD10 PARP10-IN-2 is a potent, non-selective inhibitor of mono-ADP-ribosyltransferases ARTD10 PARP10 and poly(ADP-ribose) polymerase-1 ARTD1 PARP1, exhibiting IC50 values of 2.0 μM and 9.7 μM, respectively.

PARP10 15-IN-2 (Compound 8h) is a dual inhibitor of PARP10 and PARP15, with IC50 values of 0.15 μM and 0.37 μM, respectively. It can penetrate cells and prevent apoptosis [1].

TIQ-A is a PARP1 inhibitor which involved in DNA single-strand break repair via the base excision repair pathway. PARP1 is triggered by DNA damage and its excessive activation has been proposed as a causative factor in many pathological conditions includi

ARTD10 PARP10-IN-1 is a potent PARP inhibitor of the mono-ADP ribosyltransferases ARTD7 PARP15, ARTD8 PARP14, ARTD10 PARP10 and poly ADP-ribose polymerase-1 (ARTD1 PARP1), with potential anticancer and antitumour activity for the study of prostate and breast cancers.

OUL232 is a potent single ARTs PARP7, PARP10, PARP11, PARP12, PARP14 and PARP15 inhibitor for cancer and tumour research.